Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zoll Medical wins $12 million Canadian contract
This represents the first time that the province of Quebec will standardize its entire system to one model of defibrillator, the company said. About 700 E Series defibrillators,
This represents the first time that the province of Quebec will standardize its entire system to one model of defibrillator, the company said. About 700 E Series defibrillators,
According to the company, The HairDX (RxR) genetic test for finasteride response will help doctors predetermine if patients will have a subtle, moderate, or great treatment response to
Ariad Pharmaceuticals, a developer of small-molecule drugs to treat cancer, has announced the initiation by Merck & Co, of a Phase II clinical trial to evaluate the safety
Sancuso (SP-01) is a long-acting transdermal system, delivering the anti-emetic, granisetron, steadily into the patient’s bloodstream over seven days without the need for injections or swallowing pills. Sancuso
Greenway Medical Technologies has announced that it will be deploying its electronic health record solution, PrimeSuite, into Pediatric Associates of Washington State. With this implementation, Pediatric Associates’s eight
Trelstar 22.5mg is a six-month slow release, injectable, luteinizing hormone-releasing hormone agonist indicated for the palliative treatment of advanced prostate cancer. Paladin obtained the Canadian license for Trelstar
The company’s wrinkles or nasolabial folds Phase III trials were conducted under an FDA special protocol assessment. Isolagen currently estimates that its unrestricted, available cash resources will allow
DiaMedica said that Dr Waters is an experienced scientist and pharmaceutical industry executive with more than 24 years of active leadership and involvement in drug development. Dr Waters’s
The company reported a net loss of $38.1 million, or $0.49 per share, for the full year 2008, compared to a net loss of $33.9 million, or $0.47
Net loss for the year 2008 was $8.42 million, or $0.71 per share, compared to a net loss of $8.94 million, or $0.80 per share, for 2007. The